Support for a TAVR-first approach in patients with concurrent valve and coronary disease
Five-year data demonstrate convergence of outcomes from years 1 to 5
Randomized WATCH-TAVR trial confirms safety of the combined procedures
Differences in pace of hemodynamic change signal need for sex-specific management
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Potential benefits include clinical guidance, TAVR outcome prediction, device testing
Sophisticated in vivo modeling can enhance device development and therapy testing
Observational findings over 5+ years of follow-up argue for caution in this population
Our experts recap the most notable changes and developments
Novel TAVR deployment technique improves outcomes without compromising safety
Database analysis sets stage for a multicenter trial assessing TAVR’s potential role